Reactions 1680, p165 - 2 Dec 2017 Breast invasive ductal carcinoma: case report A woman in her late 50s [age at the time of reaction onset not clearly stated] developed breast invasive ductal carcinoma following treatment with imatinib [route and outcome not stated]. In July 2012, the woman was diagnosed with chronic myeloid leukemia (CML) at the age of 56. She neither had a history of exposure to any possible carcinogenic agents nor family history of any malignancy. Later, she started receiving therapy with imatinib 400mg daily for CML and achieved complete remission. She continued to receive imatinib as a maintenance therapy. In October 2016, she observed a painless mass in her breast. Two months later when the lump grew rapidly, she sought medical attention. In December 2016, she was admitted to the breast surgery department. Physical examination showed 4.0cmx3.0cm firm palpable mass in the upper-outer quadrant of her left breast, which was not attached to the chest wall or skin. Color Doppler ultrasonography showed a circumscribed area of echogenicity, with an estimate size of 28.9mmx14.1mm, and preoperative test of peripheral blood revealed leukocyte count 9 9 of 6.19x10 /L, neutrophil count of 3.42 x10 /L, erythrocyte 12 9 count of 4.16 x10 /L, platelet count of 278 x10 /L, and haemoglobin count of 134 g/L. On 16 December 2016, she had a surgical resection. The tru-cut biopsy of the left breast mass showed ductal carcinoma in situ (DCIS), and simple resection and eventually sentinel lymph node biopsy of the left breast was performed. Pathology showed a medium grade intraductal carcinoma with local infiltration related to invasive micropapillary carcinoma components. No sentinel lymph node metastasis was found, but isolated tumour cells were present in the lymph nodes. In January 2017, she started receiving letrozole [Letrozol] treatment. Author comment: "We think it is possible that the secondary invasive micropapillary carcinoma (IMPC) in this case was associated with long-term use of imatinib." Pan L, et al. Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy. Breast Cancer 24: 790-793, No. 6, Nov 2017. Available from: URL: http:// doi.org/10.1007/s12282-017-0786-8 - China 803284809 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera